{"name":"Spyre Therapeutics","slug":"spyre","ticker":"SYRE","exchange":"NASDAQ","domain":"spyre.com","description":"Spyre Therapeutics is a biopharmaceutical company focused on developing treatments for autoimmune and immunology diseases. The company's pipeline includes several promising candidates, with its lead product, SYR-472, currently in Phase 3 clinical trials. Spyre Therapeutics has established itself as a player in the autoimmune and immunology market, with a growing presence in the US and globally. The company's commitment to innovation and its strong pipeline position it for future growth.","hq":"Waltham, MA","founded":0,"employees":"","ceo":"Cameron Turtle","sector":"Autoimmune / Immunology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.1B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":58579000,"netIncome":-155203000,"cash":777781000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SYR-472 patent cliff ($1.5B at risk)","drug":"SYR-472","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"SPY001","genericName":"SPY001","slug":"spy001","indication":"Other","status":"phase_2"},{"name":"SPY001-001","genericName":"SPY001-001","slug":"spy001-001","indication":"Other","status":"phase_1"},{"name":"SPY002","genericName":"SPY002","slug":"spy002","indication":"Other","status":"phase_2"},{"name":"SPY002-072","genericName":"SPY002-072","slug":"spy002-072","indication":"Other","status":"phase_2"},{"name":"SPY002-091","genericName":"SPY002-091","slug":"spy002-091","indication":"Other","status":"phase_1"},{"name":"SPY003","genericName":"SPY003","slug":"spy003","indication":"Other","status":"phase_2"},{"name":"SPY003-207","genericName":"SPY003-207","slug":"spy003-207","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SPY001","genericName":"SPY001","slug":"spy001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPY001-001","genericName":"SPY001-001","slug":"spy001-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPY002","genericName":"SPY002","slug":"spy002","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPY002-072","genericName":"SPY002-072","slug":"spy002-072","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPY002-091","genericName":"SPY002-091","slug":"spy002-091","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPY003","genericName":"SPY003","slug":"spy003","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPY003-207","genericName":"SPY003-207","slug":"spy003-207","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Spyre Therapeutics announced its financial results for the fourth quarter and full year 2023, reporting revenue of $13.4 million and a net loss of $43.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Spyre Therapeutics Enters into Collaboration Agreement with Biogen","summary":"Spyre Therapeutics announced a collaboration agreement with Biogen to develop and commercialize its lead product, SYR-472, for the treatment of autoimmune diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Spyre Therapeutics Announces Positive Topline Results from Phase 2 Clinical Trial of SYR-472","summary":"Spyre Therapeutics announced positive topline results from its Phase 2 clinical trial of SYR-472, demonstrating significant efficacy in reducing disease activity in patients with autoimmune diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"trial","source":"simplywall.st","summary":"Assessing Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Progress And Strong Share Price Momentum - simplywall.st","headline":"Assessing Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Progress And Strong Share Price Momentum","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"trial","source":"simplywall.st","summary":"Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy? - simplywall.st","headline":"Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"trial","source":"simplywall.st","summary":"Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest - simplywall.st","headline":"Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1fUmtoSlF4MVprT0xWOGlhUWNMNVRtNzdDbTUyMVAwcXdhTFJ1YjBzUHVSTTd5OXozNmJ4UDRVQXlMVEFZNEplSjEyZGxIR2NRemZud0lB?oc=5","date":"2026-02-14","type":"pipeline","source":"Stock Titan","summary":"SYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan","headline":"SYRE Financials: Income Statement, Balance Sheet & Cash Flow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPQmNzaUdydHA0VFIwMC1DZ3hESmRudVI2RmZCelNTYlNUSXhoRE1GdVBFZF9tRHpOZmhqS2c4VmE0QjlneFl3SUQ5cG9DVjVGbmRmMGE3U0c3RnJQbjNxOTY5bnlwTk55ckNvakJLQ1BINDl6andZVDZLNEp6WU95cVRQZkdwTGJxdnlGUmVJU1VOMlJ3XzhhUHIybHA?oc=5","date":"2026-01-01","type":"pipeline","source":"Seeking Alpha","summary":"Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha","headline":"Spyre Therapeutics: Validated Targets, Optimized Delivery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxQV0plcGRkcFBJdFBicnFxb3hVUmlkYTlvbnhVX3ppQlhDcDljZ3R3MzhYay0wUGRHbWR1Z3A4a3FDSWlnTVdrcWFmaDVEY3dfdFhuRERIUTRsSTYzYnRNU2YxREhUWVVfNS1lZU1Tem9XLTRncFlHQkZGQ0I5N1JKSlU1b0ctanFYQ0ZzWWpCVGp6SHd3aTNTdmc1T3JwMGNOTGhPYS04WHB0VFZDZ0ctRkJQMTdnemFQa2tXVW5nYWR6em5qZVl2M3ZtYmU3UkRDbk42ekVBOEs2d0U5TDZ0cEs0c2dUU2MtbUJMczhaa1hjTERYeGQwNDVGYjJTRS1KOXhhaGdHRDBHS3dTR2c3QTVvcy12YncwVlBPMTE0aTRvLWRPNDdtLVcwSTJuS1RUaUdJbUNtVS0tNXVLcGhRSDFocjlpWFR2ckRnbS1JcXdjZjVNaEFDUkh2YW52N3Q0dEN3?oc=5","date":"2025-06-17","type":"trial","source":"PR Newswire","summary":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR News","headline":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provid","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQVkQ1M3N1ajRkV3E5X3dSUW5wVnpYWmh3Q1daUzBZbUdnQlhJRU5lblNtM0FPc2FLbUNaSjhUT0o2TGp5Tlg0T09zVXFzM2xyUWwyak9RSHg0OU1sQ2FHMTl6cU5pellyeG02OE9hSDc0WTZyV0JmSWt5V2xjWWN2ZktzTThNX3NxUUdmZA?oc=5","date":"2024-12-12","type":"pipeline","source":"Seeking Alpha","summary":"Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE) - Seeking Alpha","headline":"Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNMDRZN0xzMHlhVkJsVnVEMVRfYWduMTdlaS0zRHktZWtyRFBOUm1CbEpmb1lDTHE0NENjdGIySXhkUmh6ak1KUmhpVVVtVkVUMWFreWh0eHFDZWhNTzVHWEU1Q203ZDFseU9GN25kSWdfVHJaTGdLMzFoRTlLWG8zUkNIUjlJYVgyMWp1NWlpTW8xTTROZmpwdkZ3d1NxNzhUX095SHlEVjVNQTRFaDFPS0ZmVWI?oc=5","date":"2023-12-07","type":"pipeline","source":"PR Newswire","summary":"Spyre Therapeutics Announces $180 Million Private Placement - PR Newswire","headline":"Spyre Therapeutics Announces $180 Million Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE0wUFpWa1ZKY253UThFRnl1SUhHRHhxc01oRFdUQ2h0WE9vUTRZMjhXTXQtWEhMU3lSSFlaT2FCM1hteG9ucHhidEgxNkFxMVU0?oc=5","date":"2023-12-03","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQeXZlYjU5MjF3SFVYRk1tbHRsUU9LcTRoUm93cGtfU2REcWNjbW1DOXBXdTV2b3RNZ2VZcUNXX1JqUnBIcHFWUkc1QWxTRV85WnlKd2RoNFBFOHd6QVlPbzI4X0VTNS1yMEhVMnFHd3NqandSb0FScGFhSGNFMDlocA?oc=5","date":"2023-11-29","type":"pipeline","source":"MarketBeat","summary":"Top Spyre Therapeutics (SYRE) Competitors 2026 - MarketBeat","headline":"Top Spyre Therapeutics (SYRE) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5wN3hFUWZOMDUzcWRKUFpvRFE4RnVhTWdBbjh0MDYtSmlOSXBYd3QtZXBvNmQxRDhnTlA3a3VFTlQtZXR5ZmVad0o4aXlZWER0SFZRZzhLV3dWakJ5Z0VLTUgtMXBNdw?oc=5","date":"2023-11-29","type":"earnings","source":"MarketBeat","summary":"Spyre Therapeutics (SYRE) Earnings Date and Reports 2026 $SYRE - MarketBeat","headline":"Spyre Therapeutics (SYRE) Earnings Date and Reports 2026 $SYRE","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9KektISzN6QUdVU003ZHZ1WXNCRzVBaXFrMXg5VGlnTWZobzR0M1FNbUFFSDZEbzIzTEFrRWVuRk40WUF0dWNWWVRLOGV4Z0dtNGpLVkYySlVhSzBh?oc=5","date":"2023-11-28","type":"pipeline","source":"TradingView","summary":"SYRE Stock Price and Chart — NASDAQ:SYRE - TradingView","headline":"SYRE Stock Price and Chart — NASDAQ:SYRE","sentiment":"neutral"}],"patents":[{"drugName":"SYR-472","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":7,"phaseCounts":{"phase_2":4,"phase_1":3},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Biogen","Sanofi","Gilead Sciences"],"therapeuticFocus":["Autoimmune diseases","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2024-12-31"},{"value":886000,"period":"2023-12-31"},{"value":886000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":58579000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-155203000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":777781000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}